| scholarly article | Q13442814 |
| P50 | author | Tony Mok | Q61820649 |
| P2093 | author name string | D W Kim | |
| A T Shaw | |||
| R Rosell | |||
| S Peters | |||
| T Liu | |||
| S Novello | |||
| D R Camidge | |||
| A Zeaiter | |||
| E Nüesch | |||
| A Wrona | |||
| B Balas | |||
| M Pérol | |||
| S I Ou | |||
| S Gadgeel | |||
| P433 | issue | 11 | |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 2214-2222 | |
| P577 | publication date | 2018-11-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study | |
| P478 | volume | 29 |
| Q61449902 | ALK Inhibitors in the Treatment of ALK Positive NSCLC |
| Q89778188 | ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis |
| Q89497162 | Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018 |
| Q92110305 | Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells |
| Q89861115 | Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers |
| Q52318443 | Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment |
| Q91099817 | Brain metastases |
| Q58738654 | Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms |
| Q92134610 | Brain metastases in oncogene-driven non-small cell lung cancer |
| Q90731627 | Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer |
| Q89672600 | Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM) |
| Q90643260 | Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI |
| Q93059550 | Effect of Pretreatment Platelet Parameters on Survival in Limited Disease Small Cell Lung Cancer |
| Q91981779 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials |
| Q92684950 | How I treat ALK-positive non-small cell lung cancer |
| Q89636824 | Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 |
| Q92134597 | New generation anaplastic lymphoma kinase inhibitors |
| Q64100099 | Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses |
| Q91597744 | Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial |
| Q92236871 | Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives |
| Q90399052 | Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date |
| Q98223093 | ROS1-dependent cancers - biology, diagnostics and therapeutics |
| Q93110791 | Response to Selective RET Inhibition With LOXO-292 in a Patient With RET Fusion-Positive Lung Cancer With Leptomeningeal Metastases |
| Q89538761 | Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases |
| Q91895786 | Targeting anaplastic lymphoma kinase in neuroblastoma |
| Q90053588 | The Impact of Targeted Therapy on Intracranial Metastatic Disease Incidence and Survival |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q90688022 | Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists |
Search more.